Topic
Drug Approvals
51 published works
Big Molecule Watch
FDA Approves Lupin’s Ranibizumab Biosimilar
On June 5, Lupin announced that the U.S. Food and Drug Administration (“FDA”) approved RANLUSPEC, a ranibizumab biosimilar to Genentech’s LUCENTIS®. RANLUSPEC, which received European Marketing Authorization earlier this year,…
Life Sciences Perspectives
FDA’s Push for “Radical Transparency”: Key Takeaways from the Agency’s Publication of Complete Response Letters
By Elizabeth Mulkey|Krupa Zachariah|Deb Birnbach|Adam Slutsky
On July 10, 2025, the U.S. Food and Drug Administration (FDA) announced publication of over 200 complete response letters (CRLs) issued in response to applications submitted to FDA for approval…
Big Molecule Watch
EMA Issues Positive CHMP Opinions for Fresenius Denosumab Biosimilars
By Sam Herron
On May 27, 2025, Fresenius Kabi (“Fresenius”) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) had issued positive opinions for Fresenius’s two denosumab biosimilar candidates. The applications…
Life Sciences Perspectives
Charting a Conditional Approval Pathway for Rare Disease Drugs – A Top Priority for a Revamped FDA?
By Julie Tibbets|Elizabeth Mulkey
On April 18, U.S. Food and Drug Administration (FDA) Commissioner Marty Makary announced plans to roll-out a new approval pathway for rare disease drugs. Commissioner Makary’s comments build on sentiments…
Drug & Device Law
Shameless Plug – Recording of CLE Webinar on the Best and Worst Prescription Drug/Medical Device Decisions of 2024 Now Available
By Bexis
For any of our loyal readers looking to start the New Year with a healthy helping of CLE credit, a friendly reminder that four of your bloggers – Bexis, Steven…
Life Sciences Perspectives
New Momentum for a Time-Limited Conditional Approval Pathway for Rare Disease Drugs
By Julie Tibbets|Matt Wetzel|Sukrti Thonse
On October 4, 2024, a US House version of the revised Promising Pathway Act (PPA) 2.0 was introduced, sponsored by Rep. Bruce Westerman (R-AR). The bill (H.R.9938) mirrors a US…
Food Poison Journal
FDA weighs in on more Active Investigations
Big Molecule Watch
FDA Approves Sandoz’s ENVEEZU™ (aflibercept-abzv)
By Lihui Bai
On August 12, 2024, Sandoz announced that the FDA has approved ENVEEZUTM (aflibercept-abzv) 2 mg vial kit and pre-filled syringe for intravitreal injection. ENVEEZUTM is indicated for the treatment of…
Big Molecule Watch
FDA Approves Sandoz Denosumab Biosimilars
By Emma Murray
On March 5, Sandoz announced that the FDA approved its denosumab biosimilars, WYOST and JUBBONTI, as interchangeable with Amgen’s XGEVA and PROLIA. These are the first and only FDA-approved denosumab biosimilars. …
Big Molecule Watch
Denosumab Biosimilar Updates
By Keith Zullow
Celltrion Submits Denosumab BLA to FDA: On November 30, 2023, it was reported that Celltrion had completed submission of its application to the FDA for CT-P41, its denosumab biosimilar of…